Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 2/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.48 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9814678 | 0.87 | PGK1 (0.41) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL13628507 | 0.79 | ADRB1 (0.48) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL1080740 | 0.79 | TP53 (0.52) | TSHRALDH1A1TDP1 | |
| SCHEMBL10723269 | 0.78 | ADRB1 (0.52) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL11241615 | 0.78 | ADRB1 (0.52) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL6752527 | 0.78 | TP53 (0.55) | ALDH1A1OPRK1HSD17B2TDP1ACHE | |
| SCHEMBL29748919 | 0.78 | CES2 (0.47) | ACHE | |
| SCHEMBL4179038 | 0.78 | TGM2 (0.43) | SLC6A3ALDH1A1CYP3A4 | |
| SCHEMBL907672 | 0.78 | ACP3 (0.43) | ADRB1TSHRADRB2ADRB3LMNA | |
| SCHEMBL2754745 | 0.78 | SLC6A3 (0.36) | HIF1ARAB9ASLC6A3ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3796905-B1 | ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASES | UNIV ILLINOIS (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250223264-A1 | ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-07-10 | — | — | US | disclosed |
| US-12286407-B2 | Estrogen receptor beta ligands for the prevention and treatment of multiple sclerosis (MS) and other demyelinating, inflammatory and neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-04-29 | — | — | US | disclosed |
| US-20230357161-A1 | ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-09 | — | — | US | disclosed |
| US-20230357161-A1 | ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-09 | — | — | US | disclosed |
| US-11673866-B2 | Estrogen receptor beta ligands for the prevention and treatment of multiple sclerosis (MS) and other demyelinating, inflammatory and neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673866-B2 | Estrogen receptor beta ligands for the prevention and treatment of multiple sclerosis (MS) and other demyelinating, inflammatory and neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-06-13 | — | — | US | disclosed |
| US-20210230121-A1 | ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-07-29 | — | — | US | disclosed |
| US-20210230121-A1 | ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-07-29 | — | — | US | disclosed |
| EP-3796905-A1 | ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASES | The Board of Trustees of the University of Illinois (US) | 2021-03-31 | — | — | EP | disclosed |
| US-6451957-B1 | (Hydroxyalkyl)phenols, method for their preparation, and uses thereof | GENERAL ELECTRIC COMPANY | 2002-09-17 | — | — | US | disclosed |
| WO-2001046103-A1 | (HYDROXYALKYL)PHENOLS, METHOD FOR THEIR PREPARATION, AND USES THEREOF | GENERAL ELECTRIC COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230121-A1 | ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASES | ESR2, ESRRG, GPER1 | ADRB1 170/4885ADRA1A 436/4885MIF 515/4885 |
| US-12286407-B2 | Estrogen receptor beta ligands for the prevention and treatment of multiple sclerosis (MS) and other demyelinating, inflammatory and neurodegenerative diseases | ESR2, ESRRG, GPER1 | ADRB1 170/4885ADRA1A 436/4885MIF 515/4885 |
| US-11673866-B2 | Estrogen receptor beta ligands for the prevention and treatment of multiple sclerosis (MS) and other demyelinating, inflammatory and neurodegenerative diseases | ESR2, ESRRG, GPER1 | ADRB1 170/4885ADRA1A 436/4885MIF 515/4885 |
| US-20230357161-A1 | ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASES | ESR2, ESRRG, GPER1 | ADRB1 170/4885ADRA1A 436/4885MIF 515/4885 |
| US-20250223264-A1 | ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASES | ESR2, ESRRG, GPER1 | ADRB1 170/4885ADRA1A 436/4885MIF 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.